Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs SiTime Corporation (SITM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs SiTime Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B), while SiTime Corporation trades at $679.01 (market cap $20.05B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and SiTime Corporation is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | SITM | |
|---|---|---|
Market Cap | $29.60B | $20.05B |
Sector | Health | Technology |
52-Week High | $491.22 | $901.60 |
52-Week Low | $205.48 | $212.77 |
Enterprise Value | $27.56B | $19.45B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
SITM trades at $680.52, down 1.37% on the day, with a bullish technical outlook supported by moving averages and key resistance at $687. The company reported strong Q2 2026 earnings of $2.34 per share, beating estimates, with revenue surging 127% year-over-year driven by AI infrastructure demand. Analyst consensus is unanimously bullish with a $870 price target, reflecting optimism around the Renesas acquisition and AI timing growth.
The outlook for SITM is positive given robust earnings beats, AI-driven revenue expansion, and solid institutional support. However, risks include premium valuation multiples, integration challenges from the Renesas deal, and dependence on cyclical tech spending. Investors should weigh high growth potential against execution risks in a competitive semiconductor market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →
